National Pension Service increased its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 3.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,439,182 shares of the biopharmaceutical company’s stock after purchasing an additional 498,289 shares during the quarter. National Pension Service’s holdings in Pfizer were worth $334,636,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. State Street Corp lifted its holdings in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Geode Capital Management LLC lifted its holdings in Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares during the period. Northern Trust Corp lifted its holdings in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the period. Finally, Fisher Asset Management LLC lifted its holdings in Pfizer by 5.4% in the fourth quarter. Fisher Asset Management LLC now owns 51,952,106 shares of the biopharmaceutical company’s stock worth $1,293,607,000 after purchasing an additional 2,664,052 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer and Innovent Biologics announced a global licensing and collaboration deal to research and develop 12 early-stage cancer medicines, with potential value of up to $10.5 billion. The agreement expands Pfizer’s oncology pipeline and could create long-term revenue opportunities. Reuters article
- Positive Sentiment: The companies also described the partnership as a strategic global collaboration covering ADCs and multi-specific antibodies, which suggests Pfizer is strengthening its next-generation cancer portfolio. PR Newswire article
- Positive Sentiment: Recent coverage also highlighted steady early-stage pipeline progress, including a new Phase 1 trial update, reinforcing the view that Pfizer has several development programs moving forward. TipRanks article
- Neutral Sentiment: Bank of America recently lifted its price target on Pfizer to $27 from $26 after stronger quarterly results, indicating slightly improved sentiment but still a cautious overall stance. Yahoo Finance article
Pfizer Price Performance
Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the business earned $0.92 earnings per share. Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.
Pfizer Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Monday, March 2nd. CICC Research assumed coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Finally, UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.82.
View Our Latest Research Report on Pfizer
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
